Board of Non-Executive Directors
Eduardo Bravo is CEO of Dutch biotech company, Cytrill, and has held many leadership positions in the biopharmaceutical industry over the last three decades. Until March 2023 he was the CEO of EBAC, a Nasdaq listed SPAC sponsored by LSP that merged with Oculis, a European biotech company focused on ophthalmology.
In his 30 years of senior management and board experience, Eduardo has been CEO of Nordic Nanovector, TiGenix and Cellerix, and before that held several senior management positions at Sanofi-Aventis and SmithKline Beecham. As CEO of TiGenix, he oversaw several financing rounds, the company’s IPO on Nasdaq and its eventual acquisition by Takeda in 2018.
Eduardo is currently Chairman of the Board at Vivet Therapeutics and Engitix Ltd and he was President of the European Biopharmaceutical Enterprises Board of Directors between 2016 and 2018.
Olivier Litzka, PhD
Olivier Litzka is a Partner at Andera Partners and a Director of the Board of Ariceum. Olivier has a Ph.D. in molecular microbiology from the LMU in Munich. He started his business career in 1998 with Mercer Management Consulting. In 2000, Olivier joined 3i Group plc with a focus on biopharma and medtech investments, first based in Munich, later in 3i’s Paris office.
In 2006, Olivier joined as a partner Andera Partners’ BioDiscovery team and contributed to grow the company to one of the leading Life Sciences Venture Capital investors in Europe. Olivier was on the board of multiple companies which got acquired or went public. Currently he is involved in several biotech and medtech startups in Europe and the U.S.
Christoph Massner, PhD
Christoph is a Principal at the Earlybird Venture Capital Health Fund, which he joined in 2018. Earlybird Health invests in European health companies across the sectors of biopharma, medical devices, diagnostics & platform technologies and digital health. Currently, he serves as a board director of wellabe and as a board observer of Alesi Surgical. Before joining Earlybird, Christoph conducted research in different laboratories in Germany and Australia for +7 years.
Christoph graduated in Technical Biology from the University of Stuttgart and holds a PhD in Synthetic Biology from the Technical University of Munich.
Joachim Rothe, PhD
Joachim (JR) Rothe is a Partner in the EQT Life Sciences team. JR was Managing Partner at LSP from 2001 until 2022, when LSP joined forces with EQT and was renamed EQT Life Sciences. Prior to joining LSP, JR worked in a number of increasingly senior roles at Roche, McKinsey and MPM Capital in Cambridge, USA.
JR graduated from FU University Berlin (Germany) and gained his Ph.D. in Molecular Immunology from Freiburg University (Germany).
Per is a partner at HealthCap. HealthCap is a family of venture capital funds investing globally in life sciences. With more than EUR 1.2 billion raised since its start in 1996, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe. Prior to joining HealthCap as a partner in 2000, Per gained over 15 years of investment banking experience, mainly with ABB Aros Securities in Sweden. In his last position with ABB Aros Securities, as a Director in the firm’s corporate finance department, he specialized in the areas of merger transactions, initial public offerings and equity incentive programs. Prior to this Per was Head of Research, also at ABB Aros Securities.
Per received his M.Sc. in Engineering from the Institute of Technology in Linköping.
Martin Münchbach, PhD
Martin is a founding partner of Pureos Bioventures where he holds the position of Managing Partner. He has been a venture capital investor since 1999, investing in life science companies across all stages and types. Prior to Pureos, he was senior investment advisor private equity at Bellevue Asset Management. Martin’s most successful investments and board assignments include Radius Health, Molecular Partners, Optimer, Axovan and Glycart. In addition to Ariceum, Martin is currently a Board member at Ypsomed Holding, Alentis Therapeutics, binX Health and River Renal.
Martin obtained his PhD in Protein Chemistry and his MAS in Management, Technology and Economics from ETH Zurich.
Jean-Patrick Hennebelle is currently Vice-President of Late Stage Partnering at Ipsen, and he represents the company as Board Observer.
Jean-Patrick has over 20 years of experience in global business development and acquisitions within the pharmaceutical industry and is responsible for driving Ipsen’s partnering activities across its key therapeutic areas of oncology, neuroscience and rare diseases for all projects beyond Phase 3. He has an extensive track record of creating successful business development deals in Europe, Asia and North America. Prior to joining Ipsen, Jean-Patrick worked at various pharmaceutical companies in business development and business unit management and originally started his career at EY in strategic consulting.
Jean-Patrick has a bachelor’s degree from Skema Business School and received an MSc in Corporate Finance from ESCP in Paris.